Benzinga | Jun 29, 2021 07:50AM EDT

Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $149

Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $114 to $149.